The suitability of radiomics extracted from 4DCT motion‐compensated reconstruction
Journal of Applied Clinical Medical Physics · 2025
DOI: 10.1002/acm2.70254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2025. Verfasst von Chelsea A H Sargeant und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Lung Neoplasms, Four-Dimensional Computed Tomography, Algorithms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The most appropriate 4DCT image for radiomics analysis remains uncertain, with options including individual respiratory phases and motion‐compensated (MC) reconstructions. This study compares radiomic features derived from MC reconstructions and patient‐specific, 4D phases, evaluating their influence on feature selection, robustness to registration algorithms and implications for radiomics analysis.
Methods
This study included 223 NSCLC patients. MC reconstructions (MC mean and MC median ) were generated using three different registration algorithms and compared to a patient‐specific optimal 4D phase (TOp), defined as the phase where radiomic feature values exhibited the smallest variability. Ninety‐three features, extracted from the tumor region, underwent unsupervised selection to assess how image type influenced feature selection and redundancy. The impact of image type on distant failure prediction was evaluated using bootstrapped univariable Cox regression ( p < 0.05) and multivariable modeling. Model performance was assessed across 500 bootstrap resamples, with feature selection frequency, concordance index (CI), and Akaike Information Criterion (AIC) recorded.
Results
Over 60% of selected features differed between 4D phases and MC reconstructions, indicating image type influences feature selection. The proportion of remaining features varied: 11.8% (TOp), 15.1% (MC mean ), and 12.9% (MC median ). The single‐phase model, TOp, achieved a CI of 0.72 [0.64–0.77] and an AIC of 267.53, but did not demonstrate clear superiority over MC‐based models. Both MC median and TOp showed modest improvements over the clinical model, suggesting both image types offer comparable prognostic potential. MC reconstructions were largely robust across registration algorithms, but MC mean and MC median reconstructions should not be used interchangeably.
Conclusion
This study highlights differences in radiomic feature selection and predictive performance between MC reconstructions and individual 4DCT phases. MC reconstructions were a viable alternative, demonstrating robustness across registration algorithms. Both approaches can be integrated into radiomics pipelines, but image type selection should be carefully considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK.
ORCID-Profile: Chelsea A H Sargeant
Zitieren
APA
Sargeant, C. A. H., Davey, A., & McWilliam, A. (2025). The suitability of radiomics extracted from 4DCT motion‐compensated reconstruction. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.70254
Vancouver
Sargeant CAH, Davey A, McWilliam A. The suitability of radiomics extracted from 4DCT motion‐compensated reconstruction. Journal of Applied Clinical Medical Physics. 2025. doi:10.1002/acm2.70254
BibTeX
@article{Sargeant2025,
author = {Sargeant, Chelsea A H and Davey, Angela and McWilliam, Alan},
title = {The suitability of radiomics extracted from 4DCT motion‐compensated reconstruction},
journal = {Journal of Applied Clinical Medical Physics},
year = {2025},
doi = {10.1002/acm2.70254}
}
EUVIMED